One-click Automated 3D Treatment Planning for Radiopharmaceutical Therapy

用于放射性药物治疗的一键式自动化 3D 治疗计划

基本信息

批准号：
10678173
负责人：
Joseph Grudzinski
金额：
$ 200万
依托单位：
VOXIMETRY, INC.
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-04-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10678173
关键词：
3-Dimensional Acceleration Address Adoption Algorithms Antibodies Artificial Intelligence Automation Benchmarking Biodistribution Calibration Cancer Patient Characteristics Clinic Clinical Computer software Consensus Contracts Deposition Development Disseminated Malignant Neoplasm Dose Drug Kinetics Ensure Evaluation External Beam Radiation Therapy Funding Gamma Rays Goals Grant Healthcare Systems Image Intellectual Property Lead Lymphoma Marketing Metastatic Prostate Cancer Methods Modeling Neoplasm Metastasis Neuroendocrine Tumors Normal tissue morphology Organ Overdose Patient-Focused Outcomes Patients Peptides Pharmaceutical Preparations Phase Physicians Physiology Radiation Radioactivity Radioisotopes Radiopharmaceuticals Reporting Resources Risk Route Secure Small Business Innovation Research Grant System Technology Testing Therapeutic Time Treatment outcome Tumor Tissue Validation Work absorption automated segmentation cancer therapy chemotherapy clinical decision support clinical practice clinically significant commercialization cost effective design digital dosimetry experience image registration individual patient individualized medicine neoplastic cell personalized medicine pharmacokinetic model reconstruction response side effect single photon emission computed tomography small molecule theranostics tool treatment planning tumor uptake user-friendly verification and validation

项目摘要

PROJECT SUMMARY/ABSTRACT The Radiopharmaceutical Therapy (RPT) market is projected to surpass the Technitium-99m market by 2025, with an emphasis on metastatic prostate cancer, neuroendocrine tumors, and lymphoma. Driven by well- tolerated treatments and fewer side-effects, experts have estimated 150 new theranostic centers will be needed in the U.S. to deliver an estimated 50,000–200,000 treatment cycles/year. Currently, all RPT treatments administer a standard therapeutic dose despite unique patient physiology and pharmacokinetics. From experience with external beam radiation therapy (EBRT), we know that patient-specific prescriptions based on absorbed dose leads to better patient outcomes. A key technology required to enable this personalization is fast, accurate, whole-body patient-specific dosimetry. In a prior Phase II SBIR, Voximetry was able to integrate our fully benchmarked and IP-protected Monte Carlo dosimetry algorithm into a cost-effective RPT treatment planning solution (TorchTM) by adding additional features such as image registration, contour propagation, and voxel-based pharmacokinetic (PK) modeling. Torch was designed to model uptake and clearance routes of any drug class (e.g., small molecules, peptides, antibodies) and any radionuclide, effectively adding a ‘swiss army knife’ tool into the clinician’s RPT toolkit. Leveraging the gamma rays emitted by the RPT agent, Torch can calculate how much radiation energy is deposited within each voxel of organs and tumors throughout the body. Estimates of voxel-level whole-body patient-specific dosimetry are better correlated with response than the standard uptake value (SUV) information that is clinically available today. Using this approach, Voximetry has developed a fast, accurate, RPT treatment planning solution aimed to inform clinicians with extremely accurate voxel-based Monte Carlo (MC) dosimetry in a matter of minutes. Additionally, Vox has developed a GPU accelerated Monte Carlo SPECT reconstruction algorithm that leads to dosimetry estimates which differ from conventional reconstruction algorithms by at least 25%, which is seen as clinically significant. This information will support clinical decisions to personalize safe therapeutic doses. Automation of this RPT dosimetry workflow is especially important for healthcare systems that would like to implement dosimetry-guided therapy in clinical practice but are currently ill-equipped in terms of expertise and resources to perform advanced dosimetry for RPT. By enabling automation, Vox will ultimately benefit cancer patients by making available a personalized treatment that targets metastatic cancer that in many cases is more efficacious and has fewer side effects than chemotherapy. The specific aims that will be accomplished in the proposal are to (1) Develop automated segmentation tools for organs and risk and tumors using artificial intelligence, (2) develop scanner calibration, partial volume correction, and Monte Carlo reconstruction to ensure accurate SPECT imaging, and (3) automate, implement, and validate end-to-end clinical Torch workflow. The successful completion of these aims will help break down barriers to commercialization and accelerate market adoption of Torch.

项目概要/摘要预计到 2025 年，放射性药物治疗 (RPT) 市场将超过 Technitium-99m 市场，重点关注转移性前列腺癌、神经内分泌肿瘤和淋巴瘤。由于治疗的耐受性和副作用较少，专家估计将需要 150 个新的治疗中心在美国，每年提供估计 50,000-200,000 个治疗周期目前，所有 RPT 治疗均已完成。尽管患者生理学和药代动力学独特，但仍给予标准治疗剂量。外照射放射治疗 (EBRT) 的经验表明，我们知道基于患者的特定处方吸收剂量可以带来更好的患者治疗结果，实现这种个性化所需的关键技术是快速、在之前的 II 期 SBIR 中，Voximetry 能够整合我们的准确、全身患者特异性剂量测定。将完全基准化且受知识产权保护的蒙特卡洛剂量测定算法转化为经济高效的 RPT 治疗规划解决方案（TorchTM），通过添加图像配准、轮廓传播和 Torch 旨在模拟任何药物的摄取和清除途径。药物类别（例如小分子、肽、抗体）和任何放射性核素，有效地增加了一支“瑞士军队” Torch 可以将“刀”工具纳入临床医生的 RPT 工具箱中，利用 RPT 剂发射的伽马射线。计算全身器官和肿瘤的每个体素内沉积了多少辐射能量。体素水平全身患者特异性剂量测定的估计与反应的相关性比当今临床上可用的标准摄取值 (SUV) 信息使用这种方法，Voximetry 已实现。开发了快速、准确的 RPT 治疗计划解决方案，旨在向内部人士提供极其准确的信息仅需几分钟即可完成基于体素的蒙特卡罗 (MC) 剂量测定此外，Vox 还开发了 GPU。加速蒙特卡罗 SPECT 重建算法导致剂量测定估计不同于传统重建算法至少提高了 25%，这一信息被视为具有临床意义。将支持临床决策以个性化安全治疗剂量的自动化 RPT 剂量测定工作流程。对于希望在临床中实施剂量测定指导治疗的医疗保健系统尤其重要实践，但目前在专业知识和资源方面装备不足，无法进行高级剂量测定通过实现自动化，Vox 最终将通过提供个性化服务使癌症患者受益。针对转移性癌症的治疗在许多情况下比传统疗法更有效且副作用更少该提案将实现的具体目标是（1）开发自动化。使用人工智能进行器官、风险和肿瘤的分割工具，(2) 开发扫描仪校准，部分体积校正和蒙特卡罗重建，以确保准确的 SPECT 成像，以及 (3) 自动化，实施并验证端到端临床 Torch 工作流程将有助于成功完成这些目标。打破商业化障碍并加速 Torch 的市场采用。